Highlights: Positive topline results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression; rapid and sustained response for patients receiving a single 25mg dose of COMP360 psilocybin with psychological support Launch of phase II study of COMP360 psilocybin therapy for PTSD Positive signals from Maryland Oncology Hematology open-label investigator initiated study of…


Previous articlePTSF84 – A Brief Check-in From Wonderland
Next articlePsychedelic Bulletin: Deconstructing COMPASS Pathways’ Phase 2b Results